TAMPA, FL – Morphogenesis Inc., a Florida corporation with headquarters in Tampa, FL, announces its plans to raise up to $2 million from the sale of its common stock to accredited investors. The company’s Private Placement Memorandum is expected to be available for review later this month.
Morphogenesis Inc. (www.morphogenesis-inc.com) is an 18-year-old, privately-held biotechnology company which conducts ground-breaking research in the rapidly growing cell therapy, biologics and tissue engineering fields.
Morphogenesis has developed, and is primarily focused on, its multi-indication therapeutic cancer vaccine called, ImmuneFx™, which educates the patient’s own immune system to attack tumor cells throughout the body without damaging normal cells or systems.
Several leading authorities project the annual therapeutic cancer vaccine market to expand to $8 billion within the next six years. Experts predict that within the next 10 years, 50 percent of cancer treatments will involve immunotherapy.
Its wholly-owned subsidiary, Veterinary Oncology Services Inc., assists veterinary oncology physicians in providing this non-toxic therapy in a personalized treatment form for many types of cancers in dogs, cats and horses. Because the immune systems and cancers in companion animals and people are essentially the same, it is expected that if and when approved by the FDA, the therapy will prove equally successful in treating multiple human cancers.